Skip to main content
PTCT
NASDAQ Life Sciences

PTC Therapeutics Raises 2026 Guidance After Strong Q2: $361M Revenue, $2.2B Cash, New Board Member

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$77.01
Mkt Cap
$6.264B
52W Low
$43.175
52W High
$90.87
52W Position info
78% above low
Off High info
15% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

PTCT sits 78% above its 52-week low of $43.175.

Summary

PTC Therapeutics reported Q2 2026 revenue of $361 million, raised full-year guidance, and swung to profitability. The company also appointed a new board member.


Key Events · Earnings and Guidance · PTCT

  • Q2 Revenue Beats, Profitability Returns

    Total revenue of $361 million, including $239 million in product revenue, drove net income of $83.5 million compared to a $64.8 million loss in Q2 2025.

  • Full-Year Guidance Raised

    2026 total revenue guidance increased to $1.18–$1.28 billion, with product revenue guidance raised to $850–$950 million from $750–$850 million.

  • Strong Cash Position

    Cash, cash equivalents, and marketable securities totaled $2.2 billion as of June 30, 2026, bolstered by a $550 million convertible note offering.

  • Sephience Launch Momentum

    Sephience revenue reached $151 million in Q2, with 1,647 patients on commercial therapy worldwide and expanding international contributions.


Analysis · PTCT · Life Sciences

PTC Therapeutics delivered a standout second quarter, with total revenue of $361 million driven by $239 million in product sales. The company raised its full-year 2026 total revenue guidance to $1.18–$1.28 billion and product revenue guidance to $850–$950 million, signaling confidence in the ongoing Sephience launch and pipeline progress. Net income swung to $83.5 million from a loss a year ago, and the cash position strengthened to $2.2 billion following a $550 million convertible note offering. The appointment of former CHRO Hege Sollie-Zetlmayer to the board adds operational depth. This filing materially updates the investment thesis with better-than-expected financials and raised outlook.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PTCT was trading at $77.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.3B. The 52-week trading range was $43.18 to $90.87. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PTCT - Latest Insights

PTCT
Nov 03, 2026, 7:00 AM EST
Source: PR Newswire
Importance Score:
7
Price at Filing: $61.39
Real-time Price: $56.41 info
Change: -$4.98 (-8%) info
Market Cap: $4.719B info
PTCT
Oct 29, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $62.00
Real-time Price: $56.41 info
Change: -$5.59 (-9%) info
Market Cap: $4.719B info
PTCT
Oct 29, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $60.00
Real-time Price: $56.41 info
Change: -$3.59 (-6%) info
Market Cap: $4.719B info
PTCT
Oct 29, 2026, 4:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $64.57
Real-time Price: $56.41 info
Change: -$8.16 (-13%) info
Market Cap: $4.719B info
PTCT
Aug 28, 2026, 5:42 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $70.09
Real-time Price: $56.41 info
Change: -$13.68 (-20%) info
Market Cap: $4.719B info